tirzepatide surmount-1 nejm 2022 weight loss percent In the trial (published in in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor SURPASS-2 (NEJM 2021) was the
Pay in 4 interest-free payments of $7.29 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7


























